A phase II study of radiation and Docetaxel and Cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09/0201 trial.

Frédéric Viret (1), Marc Ychou (2), Charlotte Baey (3), Jaafar Bennouna (4), Antoine Adenis (1), Didier Pfeiffer (5), Françoise Mornex (4), Patrice Celier (4), Christine Montoto-Grillot (1) and Michel Ducrée (1)

(1) Institut Paoli-Calmettes, Marseille, France; (2) Centre Val d’Aurelle, Medical Oncology, Montpellier; (3) Institut Gustave Roussy, Biostatistical Unit, Villejuif; (4) Centre René Gauducheau, Medical Oncology, Nantes; (5) Centre Oscar Lambret, Medical Oncology, Lille; (6) Centre Alexis Vautrin, Radiotherapy, Nancy; (7) Hepatolung Sud, Radiotherapy, Lyon; (8) Centre Paul Paun, Medical Oncology, Angers; (9) FNCLCC, Paris, (10) Institut Gustave Roussy, Medical Oncology, Villejuif, FRANCE

ABSTRACT #4625

Material and Methods

Localy advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy. The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel + cisplatin in histologically proven adenocarcinoma of the pancreas.

RESULTS

- 51 pts (20 women and 31 men, with median age of 62 years), were included between 06/2003 and 15/2/2008.
- Location of the tumor: head (33 pts), body (2 pts), tail (13 pts) and median overall survival was 9.6 months.
- The median dose of radiotherapy received by the patients was 54 Gy. The median dose of docetaxel and cisplatin administered was 19.8 mg/m².

REFERENCES